Oblique Therapeutics:

      • is a curiosity-driven, innovative biotech company with strong scientific acumen and drive for increasing the bandwidth of antibody therapeutics, focusing on pain and aggressive metastatic cancer.
      • has a vision to be a global industry leader focused on transformative antibody medicines against pain and aggressive cancer.
      • aims at 2–3 antibody drug approvals per year within 10 years.

      Highlighted programs in the pipeline